The effects of atorvastatin in experimental autoimmune uveitis

British Journal of Ophthalmology

Volumn 89, Issue 3, 2005, Pages 275-279

  Thomas, P B ^a   Albini, T ^a   Giri, R K ^a   See, R F ^a   Evans, M ^a   Rao, Narsing A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN[161-180]; PHOSPHATE BUFFERED SALINE; RETINOID BINDING PROTEIN; STAT4 PROTEIN; STAT6 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DYSLIPIDEMIA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UVEITIS; UVEORETINITIS;

ANIMALS; AUTOIMMUNE DISEASES; BLOTTING, WESTERN; DNA-BINDING PROTEINS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1; INTERLEUKIN-2; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; PYRROLES; STAT4 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; TH1 CELLS; TH2 CELLS; TRANS-ACTIVATORS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 14744271191     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.050401     Document Type: Article

References (24)

1. Johnston TP, boker JC, Hall D, et al. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000;149:303-13.
2. Sacks FM, Pfeffer MA, Marc A, et al. The effect of pravastatin on coronary events after myocardial infraction in patients with average cholessterol levels. N Engl J Med 1996;335:1001-9.
3. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003;197:725-33.
4. Youssef S, Stuve O, Patarroyo JC. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverse paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
5. Greenwood J, Walters CE, Pryce G, et al. Lovastainn inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encepalomyletis. FASEB J 2003;17:905-7.
6. Xu H, Rizzo LV, Silver PB, et al. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and commited effector T cells in experimental autoimmune uveitis. Cell Immunol 1997;178:69-78.
7. Caspi RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 2002;21:197-208.
8. Silver PB, Chan C, Wiggert B, et al. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-905.
9. Hankey JR, Lightman SL, Baker D. Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10. RIII mice: characterization of disease parameters and immunomodulation, Exp Eye Res 2001;72:341-50.
10. Giri RK, Selvaraj SK, Kalra VK. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 2003;15:5281-94.
11. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
12. Cuthbert JA, Lipsky PE. Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 1981;126:2093-9.
13. Cutts JL, Scallen TJ, Watson J, et al. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989;139:550-7.
14. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.
15. Pahan K, Sheikh FG, Namboodiri AM, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-9.
16. Kwak B, Mulhaupt F, Myit S, et al. Statins(HMG-CoA reductase inhibitors) as a novel type of immunosuppressor. Nat Med 2000;6:1399-402.
17. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
18. Vollmer T, Durkalski V, Tyor W, et al. An open-label, single arm study of simvistatin as a therapy for multiple sclerosis. Abstract presented at the American Academy of Neurology, April, 2003.
19. Kiener P, Davis PM, Murray JL, et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001;1:105-18.
20. Rao NA. Role of oxygen free radicals in retinal damage associated with experimental uveitis. Trans Am Ophthalmol Soc 1990;88:797-850.
21. Palinski W. Immunomodulation; a new role for statins? Nat Med 2000;6:1311-12.
22. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998;88:4-13.
23. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
24. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 2000;95:3183-90.